Search results for "RADIOTHERAPY"

showing 10 items of 473 documents

Characterization of phenolic pellets for ESR dosimetry in photon beam radiotherapy

2017

This work deals with the dosimetric features of a particular phenolic compound (IRGANOX 1076 ® ) for dosimetry of clinical photon beams by using electron spin resonance (ESR) spectroscopy. After the optimization of the ESR readout parameters (namely modulation amplitude and microwave power) to maximise the signal without excessive spectrum distortions, basic dosimetric properties of laboratory-made phenolic dosimeters in pellet form, such as reproducibility, dose–response, sensitivity, linearity and dose rate dependence were investigated. The dosimeters were tested by measuring the depth dose profile of a 6 MV photon beam. A satisfactory intra-batch reproducibility of the ESR signal of the …

Models MolecularPhotonBiophysicsMolecular ConformationIRGANOX 1076 ®RadiationSignal030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineNuclear magnetic resonancePhenolsDosimetryDosimetrySpectroscopyMicrowavesRadiometryGeneral Environmental ScienceESRReproducibilityPhotonsDosimeterRadiationPhenolRadiotherapy2300ChemistryElectron Spin Resonance SpectroscopyRadiotherapy DosagePhotonBiophysic030220 oncology & carcinogenesisMicrowaveMicrowave
researchProduct

Coronectomy - An alternative approach to remove impacted teeth in oncological patients.

2018

Background Coronectomy involves the section of the tooth crown leaving the roots in the socket. Possibility of inferior alveolar nerve injury and mandibular fracture are the main indications for this approach. Herein, we describe a case series of coronectomy to highlight its indication in normal and oncological patients. Material and methods A total of 9 patients were submitted to coronectomy, 6 of them were oncological. Three patients were evaluated before head and neck radiotherapy (HNRT), 2 after HNRT and 1 before bone marrow transplantation. Results Mean age of the patients was 49 years, most of them male (n=7). Lower third molars were the main teeth that received this procedure, and al…

MolarBone marrow transplantationMandibular fractureMandibular canalDentistryInferior alveolar nerveTooth crown03 medical and health sciences0302 clinical medicineHead and neck radiotherapystomatognathic systemCoronectomymedicineimpacted teethpostoperative complicationoncological patients030223 otorhinolaryngologyGeneral Dentistrybusiness.industryResearchMean age030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]//purl.org/pe-repo/ocde/ford#3.02.14 [https]stomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASOdontostomatology for the Disabled or Special PatientsbusinessJournal of clinical and experimental dentistry
researchProduct

Implications of irradiating the subventricular zone stem cell niche

2016

Radiation therapy is a standard treatment for brain tumor patients. However, it comes with side effects, such as neurological deficits. While likely multi-factorial, the effect may in part be associated with the impact of radiation on the neurogenic niches. In the adult mammalian brain, the neurogenic niches are localized in the subventricular zone (SVZ) of the lateral ventricles and the dentate gyrus of the hippocampus, where the neural stem cells (NSCs) reside. Several reports showed that radiation produces a drastic decrease in the proliferative capacity of these regions, which is related to functional decline. In particular, radiation to the SVZ led to a reduced long-term olfactory memo…

NeurogénesisNeoplasias encefálicasCarcinogenesisSubventricular zoneNeurogenesis:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms [Medical Subject Headings]Brain tumorSubventricular zoneBrain damageBiologyBrain tumorsArticle03 medical and health sciencesLateral ventricles0302 clinical medicineRadioterapiaLateral VentriclesGliomamedicineAnimalsHumans:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Nerve Tissue::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Glioma [Medical Subject Headings]Stem Cell Nichelcsh:QH301-705.5:Anatomy::Cells::Stem Cells::Neural Stem Cells [Medical Subject Headings]Medicine(all)Neural stem cellsRadiationDentate gyrus:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Radiotherapy [Medical Subject Headings]NeurogenesisBrainCell BiologyGeneral MedicineAnatomymedicine.diseaseCélulas-madre neuralesNeural stem cellBrain tumormedicine.anatomical_structurelcsh:Biology (General)nervous system030220 oncology & carcinogenesis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings]medicine.symptomNeuroscience030217 neurology & neurosurgeryDevelopmental BiologyStem Cell Research
researchProduct

Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy

2019

Erbium 169Er is one of the most interesting radiolanthanides for new potential receptor-targeted β− therapy applications due to its low energy β− emissions, very low intensity ɣ rays and the possibility to use 68Ga or 44Sc as companion for diagnostic in a theranostics approach. Currently it can be produced in reactors through the neutron activation of highly enriched 168Er. The low specific activity of the produced carrier-added 169Er is limiting its use for receptor-targeted therapy. Nonetheless it is used for radiosynoviorthesis of small joints. The aim of this work is to develop a new large-scale production method for the supply of very high specific activity 169Er. Highly enriched 168Er…

Nuclear and High Energy PhysicsHIGH SPECIFIC ACTIVITIESMaterials scienceTargeted Radiotherapychemistry.chemical_elementLASER IONIZATION7. Clean energy030218 nuclear medicine & medical imaginglaw.inventionErbium03 medical and health sciences0302 clinical medicinePRECLINICAL STUDIESlaw[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Production (economics)HIGH SPECIFIC ACTIVITYIrradiationInstrumentationComputingMilieux_MISCELLANEOUSATOM LASERSRadiochemistrySELECTIVE IONIZATIONNuclear reactorERBIUMRESONANT LASER IONIZATIONLARGE SCALE PRODUCTIONSchemistryHigh specific activityER-169030220 oncology & carcinogenesisSEPARATION EFFICIENCYTARGETED RADIOTHERAPYIONIZATIONSpecific activityRECEPTOR-TARGETED THERAPYNeutron activationNUCLEAR REACTORSNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

The FIRST experiment at GSI

2012

The FIRST (Fragmentation of Ions Relevant for Space and Therapy) experiment at the SIS accelerator of GSI laboratory in Darmstadt has been designed for the measurement of ion fragmentation cross-sections at different angles and energies between 100 and 1000 MeV/nucleon. Nuclear fragmentation processes are relevant in several fields of basic research and applied physics and are of particular interest for tumor therapy and for space radiation protection applications. The start of the scientific program of the FIRST experiment was on summer 2011 and was focused on the measurement of 400 MeV/nucleon 12C beam fragmentation on thin (8 mm) graphite target. The detector is partly based on an alread…

Nuclear and High Energy PhysicsIon beamPhysics::Instrumentation and Detectorsmedicine.medical_treatmentNuclear physics[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]ScintillatorElementary-particleFIRST7. Clean energy01 natural sciencesParticle detectorWire chamberNuclear physicsDipole magnetFragmentationPARTICLE THERAPYhadrontherapy; fragmentation; nuclear physics; elementary-particle; instrumentation; experimental methodsHadrontherapy0103 physical sciencesmedicineNeutron detectionddc:530Gaseous detectorION-BEAM010306 general physicsNuclear ExperimentDETECTORInstrumentationGEANT4PARTICLE THERAPY; FLUKA CODE; ION-BEAM; FRAGMENTATION; BENCHMARKING; RADIOTHERAPY; TRANSPORT; DETECTOR; GEANT4; FIRSTPhysicsParticle therapyTime projection chamber010308 nuclear & particles physicsExperimental methodsDetectorScintillatorTRANSPORTSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Hadrontherapy; Fragmentation; Nuclear physics; Elementary-particle; Experimental methods; InstrumentationFLUKA CODEBENCHMARKINGElementary-particle; Experimental methods; Fragmentation; Hadrontherapy; Instrumentation; Nuclear physics; Instrumentation; Nuclear and High Energy PhysicsRADIOTHERAPY
researchProduct

Analysis of the response of PVA-GTA Fricke-gel dosimeters with clinical magnetic resonance imaging

2018

Abstract Fricke gel dosimeters produced with a matrix of Poly-vinyl alcohol (PVA) cross-linked with glutaraldehyde (GTA) were analyzed with magnetic resonance imaging (MRI). Previous studies based on spectrophotometry showed valuable dosimetric features of these gels in terms of X-ray sensitivity and diffusion of the ferric ions produced after irradiation. In this study, MRI was performed on the gels at 1.5 T with a clinical scanner in order to optimize the acquisition parameters and obtain high contrast between irradiated and non-irradiated samples. The PVA gels were found to offer good linearity in the range of 0–10 Gy and a stable signal for several hours after irradiation. The sensitivi…

Nuclear and High Energy PhysicsXylenol orangeMaterials scienceSettore ING-IND/20 - Misure E Strumentazione NucleariDose profileGlutaraldehydeImaging phantom030218 nuclear medicine & medical imagingMatrix (chemical analysis)Gel dosimeter03 medical and health scienceschemistry.chemical_compoundMagnetic resonance imaging0302 clinical medicineNuclear magnetic resonanceIrradiationGlutaraldehydeùInstrumentationPoly-vinyl alcoholX-ray radiotherapyDosimeterSettore FIS/01 - Fisica SperimentaleSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)chemistry030220 oncology & carcinogenesisIonization chamberAgaroseGel dosimeter; Glutaraldehyde; Magnetic resonance imaging; Poly-vinyl alcohol; X-ray radiotherapy; Nuclear and High Energy Physics; InstrumentationSettore MED/36 - Diagnostica Per Immagini E RadioterapiaNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant …

2020

Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients. Several factors, particularly morphological criteria combined with dynamic parameters, known before LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies. Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the International Liver Transplantation Society Consensus …

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularConsensusmedicine.medical_treatmentConsensus Development Conferences as TopicMEDLINE030230 surgeryLiver transplantationMedical OncologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientGrading (tumors)Societies MedicalPostoperative CareTransplantationbusiness.industryLiver NeoplasmsConsensus conferenceImmunosuppressionChemoradiotherapy Adjuvantmedicine.diseasePrognosisUnited StatesLiver TransplantationQuality of evidenceEuropeTreatment OutcomeHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth …

2020

Aim This retrospective observational study evaluated the role of hypo-fractionated stereotactic radiotherapy (SRT) in patients with oligo-progressive metastatic renal cell carcinoma (mRCC) treated with first-line oral tyrosine kinase inhibitors (TKI). Data on local control, delay of further progression, and safety are reported. Patients and methods Between January 2010 and December 2016, 28 patients with mRCC who showed oligo-progressive disease while receiving first-line pazopanib were treated with hypofractionated SRT to progressive metastatic sites to delay the change of systemic therapy. First and second progression-free survival (PFS-1 and PFS-2) were recorded, as well as objective res…

OncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentTyrosine-kinase inhibitorDisease-Free SurvivalMetastasisPazopanibRenal cell carcinomaInternal medicinetyrosine kinase inhibitorsmedicinepazopanibmetastasisHumansNeoplasm MetastasisCarcinoma Renal CellProtein Kinase InhibitorsAgedRetrospective Studiesbusiness.industryCarcinomaRenal CellRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasemetastasis; pazopanib; Renal cell carcinoma; stereotactic radiotherapy; tyrosine kinase inhibitors; Adult; Aged; Carcinoma Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective StudiesRenal cell carcinomaKidney NeoplasmsRadiation therapyOncologyToxicitystereotactic radiotherapyFemalebusinessTyrosine kinasemedicine.drug
researchProduct

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and che…

2013

HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT +/- cetuximab in the EXPERT-C trial. Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric…

OncologyAdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerReceptor ErbB-2medicine.medical_treatmentCetuximabAdenocarcinomamedicine.disease_causeAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind Methodskin and connective tissue diseasesneoplasmsNeoadjuvant therapyCapecitabineAgedProportional Hazards ModelsRetrospective StudiesCetuximabbusiness.industryRectal NeoplasmsCancerCAPOX RegimenHematologyChemoradiotherapyMiddle Agedmedicine.diseaseNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFemaleKRASFluorouracilbusinessChemoradiotherapymedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct